Pulse.

a daily field guide to health research that matters

◆ Console

‹ Wed · 28 Oct 2026
Standard addition

Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results.

Three years of gene therapy tracking shows sustained micro-dystrophin production, offering hope for slowing Duchenne muscular dystrophy progression in treated patients.

This phase iii clinical trial evaluated Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results. The abstract reports Delandistrogene moxeparvovec, an adeno-associated virus vector-based gene therapy, delivers an optimized micro-dystrophin transgene to address dystrophin deficiency in Duchenne muscular dystrophy (DMD).

What the study was

Study design
Phase III clinical trial
Population
Human participants or patients described in the PubMed abstract
Sample size
64
Category
Treatment Innovation
Maturity
Exploratory
Journal
Neurol Ther

Why it surfaced

Phase III clinical trial; PubMed abstract reviewed; conservative score reflects design, direct relevance, and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.